// App-Quantinova.ai

OP0269 (2022) : BIOMARKERS TO PREDICT RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS

Researchers

Presenter

  • Z. Szekanecz

Principal Investigators

  • C. Charles-Schoeman

  • I. Vranic

  • B. Sahin

  • S. A. Paciga

  • Z. Wang

  • C. Hyde

  • D. Martin

  • J. I. Weitz

Medical Centers

  • University of Debrecen, Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary

  • University of California Los Angeles, Division of Rheumatology, Department of Medicine, Los Angeles, CA, United States of America

  • Pfizer Ltd, Inflammation and Immunology, Tadworth, Surrey, United Kingdom

  • Pfizer Turkey, Inflammation and Immunology, Istanbul, Turkey

  • Pfizer Inc, Clinical Development and Operations, Groton, CT, United States of America

  • Pfizer Inc, Clinical Development and Operations, Groton, CT, United States of America

  • Pfizer Inc, Inflammation and Immunology, Peapack, NJ, United States of America

  • Thrombosis and Atherosclerosis Research Institute and McMaster University, Departments of Medicine and Biochemistry and Biomedical Sciences, Hamilton, ON, Canada

Locations

  • Hungary

  • United States

  • United Kingdom

  • Turkey

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

  • Rheumatoid arthritis

  • Inflammatory Arthritis

Biomarkers

  • D-dimer

  • Janus kinase

Drug/Treatment

  • Tasocitinib

  • Adalimumab

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Non Inferiority

  • Prospective

Phase

  • N/A

Study Id's

  • NCT02092467

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved